Akari Therapeutics (AKTX) surges as new KRAS pancreatic cancer data and a $5.5M financing grab investor attention

Akari Therapeutics, Plc (AKTX) is up 122.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a one-two catalyst: the company released new preclinical results for its lead ADC program AKTX-101 in KRAS-mutated pancreatic cancer models and also priced a $5.5 million private placement. In small-cap biotech, upbeat data headlines can quickly dominate trading, and the added financing news may have reinforced expectations that development work can continue near term.

Details:

Akari announced preclinical findings tied to an ASCO Annual Meeting 2026 abstract, highlighting synergistic cytotoxic activity for AKTX-101 when combined with KRAS inhibition in KRAS-mutated pancreatic cancer models.

The company said the data package supported the potential for AKTX-101 in hard-to-treat KRAS-driven tumors, a theme that often draws speculative momentum in oncology-focused microcaps.

Akari also priced a private placement expected to generate about $5.5 million in gross proceeds (before fees and expenses) to support operations and program advancement.

The financing was described as occurring in multiple tranches with closings expected between late May 2026 and mid-July 2026.

Sources:

GlobeNewswire, Barchart, RTTNews

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive AKTX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$AKTX Hedge Fund Activity

We have seen 2 institutional investors add shares of $AKTX stock to their portfolio, and 23 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ARMISTICE CAPITAL, LLC removed 2,722,993 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $14,023,413
WARBERG ASSET MANAGEMENT LLC removed 308,340 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,587,951
PALO ALTO INVESTORS LP removed 146,024 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $752,023
HIGHTOWER ADVISORS, LLC removed 79,236 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $408,065
JANE STREET GROUP, LLC removed 71,644 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $368,966
CWA ASSET MANAGEMENT GROUP, LLC removed 55,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $283,250
XTX TOPCO LTD removed 49,019 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $252,447

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$AKTX Price Targets

Multiple analysts have issued price targets for $AKTX recently. We have seen 2 analysts offer price targets for $AKTX in the last 6 months, with a median target of $14.0.

Here are some recent targets:

Sean Lee from HC Wainwright & Co. set a target price of $27.0 on 04/01/2026
Aydin Huseynov from Ladenburg Thalmann set a target price of $1.0 on 01/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.